{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/05/04/3286595/0/en/Palvella-Therapeutics-Announces-First-Patients-Dosed-in-Phase-2-LOTU-Trial-of-Fast-Track-Designated-QTORIN-Rapamycin-for-Clinically-Significant-Angiokeratomas.html", "message": "News view counter 699487 successfully enlarged"}